Drug Information

Drug General Information
Drug ID
D0P2KG
Former ID
DCL000404
Drug Name
GSK1144814
Indication Schizophrenia [ICD9: 295; ICD10:F20] Discontinued in Phase 1 [522978]
Company
GSK
Target and Pathway
Target(s) Nigral tachykinin NK(3) receptor Target Info Modulator
Substance-P receptor Target Info Modulator
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
Neuroactive ligand-receptor interaction
Measles
PANTHER Pathway CCKR signaling map ST
Reactome G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling events
WikiPathways Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
Spinal Cord Injury
GPCR downstream signaling
References
Ref 522978ClinicalTrials.gov (NCT01090440) Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects. U.S. National Institutes of Health.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.